10:33 AM EST - Eupraxia Pharmaceuticals Inc. : Announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology European Congress of Rheumatology 2024 (the "Meeting"). The EULAR Meeting is being held in Vienna, Austria from June 12-15. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading up $0.01 at $3.70.
